Semaglutide vs Revisional Surgery

A 2026 retrospective cohort found that revisional metabolic and bariatric surgery was associated with greater weight loss than semaglutide at two years among patients who had regained weight after an earlier bariatric operation. Total weight loss averaged 17.47% in the surgery group and 2.8% in the semaglutide group^[1]. This was not a randomized trial, and the abstract reports no surgical safety or complication data. The result is a comparison within one selected cohort, not proof that another operation is the better choice for every patient.

What the researchers compared

The study included 250 patients who had metabolic and bariatric surgery between 2015 and 2020 and later experienced recurrent weight gain. Of those, 120 received semaglutide and 130 underwent revisional metabolic and bariatric surgery. The surgical group included people whose previous sleeve gastrectomy was converted to Roux-en-Y gastric bypass and people whose earlier Roux-en-Y bypass was revised^[1].

The cohort was 90% female, and the average age was 41.3 years. The investigators followed body mass index and three weight-loss measures for two years after the new intervention: percentage excess BMI loss, percentage excess weight loss and percentage total weight loss^[1]. These measures use different denominators, so the percentages should not be treated as interchangeable.

This population is narrower than the general obesity population in the main semaglutide trials. Every participant had already undergone bariatric surgery and then experienced recurrent gain. The comparison therefore addresses management after an earlier operation, not whether semaglutide or surgery should be used as a first treatment for obesity. Our semaglutide evidence page covers the medicine's broader research and regulatory context.

The two-year weight results

Average BMI in the semaglutide group was 39.13 before the intervention, 37.45 at one year and 40.36 at two years. In the revisional surgery group, the corresponding averages were 41.14, 34.01 and 34.93. Between-group differences were statistically significant at one year (p=0.001) and two years (p=0.011)^[1]. The semaglutide group's average BMI being higher at two years than before treatment is a group-level observation. The abstract does not provide individual trajectories or enough information to explain why that pattern occurred.

At two years, the semaglutide group recorded 8.32% excess BMI loss, 6.1% excess weight loss and 2.8% total weight loss. The surgery group recorded 36%, 45.76% and 17.47%, respectively. The reported p values were 0.045 for excess BMI loss, 0.006 for excess weight loss and below 0.001 for total weight loss^[1]. On all three reported measures, the average result favored revisional surgery in this cohort.

The paper's conclusion is appropriately bounded. It says revisional surgery was associated with greater weight-loss outcomes at two years in this specific cohort. It also states that the absence of reported safety and complication data for the surgery group prevents a definitive comparison between the strategies^[1]. Weight change alone cannot settle a choice that also involves operative risk, recovery and the reason weight returned after the first procedure.

Why this is not a randomized head-to-head trial

The investigators looked back at care already delivered rather than randomly assigning patients to semaglutide or another operation. That design leaves room for treatment-selection differences. People sent for revision may differ from those treated with medication in anatomy, health status or clinical history, even when the reported starting averages look similar. The accessible abstract does not report an adjusted causal estimate that removes those differences^[1].

The accessible record also does not state the semaglutide dose, duration of continuous use, discontinuation rate or adherence pattern. It does not break outcomes down by the type of primary operation or the type of revision. Those details matter because conversion after sleeve gastrectomy is not the same intervention as revision of an existing gastric bypass. Without them, the 17.47% and 2.8% figures should stay attached to the study groups rather than being used as predictions for an individual patient^[2].

What the correction notices changed

The PubMed seed for this article, PMID 42560442, is a correction notice rather than the outcomes paper. It changed the author order so Rodolfo J. Oviedo appears as the second-to-last named author. It did not revise the study's sample size, methods or weight-loss results^[3]. The corrected primary article is PMID 41906069.

An earlier correction fixed the word "Weigh" to "Weight" in the title and updated Oviedo's name, ORCID and affiliation^[4]. The publisher page still displays some original wording in its citation metadata, which is why readers may encounter both title forms. Neither correction reports a change to the outcome data.

What this means in practice

The study supplies useful comparative evidence for a difficult clinical problem, but it does not produce a universal ranking. A second operation and a medication differ in reversibility, burden and risk. The reason for recurrent gain may also be anatomical, metabolic or behavioral. Those factors cannot be reconstructed from the abstract alone.

Anyone considering treatment after bariatric surgery should discuss the original procedure, current anatomy, medication history and operative risk with a bariatric team and the clinician managing obesity care. This article reports what one cohort found. It is not medical advice and does not support starting semaglutide or pursuing revisional surgery without individualized clinical assessment.

What we do not yet know

A randomized comparison with clearly reported medication exposure, adverse events and procedure-specific outcomes would answer more than this retrospective cohort can. Longer follow-up would also show whether the gap persists beyond two years. Until those data exist, the safest reading is narrow: revisional surgery was associated with greater average weight loss in this cohort, while the balance of benefit and harm remains unresolved^[1].